


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTD				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	
				Filing Date	August 26, 2003
				First Named Inventor	Pramod B. Mahajan
				Art Unit	
				Examiner Name	
Sheet	1	of	5	Attorney Docket Number	1264D

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
L S S S S S S	A2	WO 00/42205 A2	07/20/2000	Novartis-Erfindungen	Whole Document	
	A3	WO 00/12716 A2	03/09/2000	Pioneer Hi-Bred	Whole Document	
	A4	WO 99/41394 A1	08/19/1999	Pioneer Hi-Bred	Whole Document	
	A5	WO 97/08331 A1	03/06/1997	Max-Planck-Gesellschaft	Whole Document	
	A6	WO 00/15816 A3	03/23/2000	Pioneer Hi-Bred	Whole Document	
	A7	WO 99/37789 A1	07/29/1999	Pioneer Hi-Bred	Whole Document	

Examiner Signature		Date Considered	11/30/04
--------------------	---	-----------------	----------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	
		Filing Date	August 26, 2003
		First Named Inventor	Pramod B. Mahajan
		Group Art Unit	
		Examiner Name	
Sheet 2 of 5	Attorney Docket Number	1264D	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
YB	A8	CHAMANKHAH et al., Isolation of hMRE11B: failure to complement yeast mre11 defects due to species-specific protein interactions, Gene 225:107-116 (1998)	
YB	A9	TAVASSOLI et al., Cloning and characterisation of the Schizosaccharomyces pombe rad32 gene: a gen required for repair of double strand breaks and recombination, Nucleic Acids Res. 23(3):383-388 (1995)	
YB	A10	USUI et al., Complex Formation and Functional Versatility of Mre11 Budding Yeast in Recombination, Cell 95:705-716 (1998)	
YB	A11	LEE et al., Saccharomyces Ku70, Mre11/Rad50 and RPA Proteins Regulate Adaptation to G2/M Arrest after DNA Damage, Cell 94:399-409 (1998)	
YB	A12	CARNEY et al., The hMre11/hRad50 Protein Complex and Nijmegen Breakage Syndrome: Linkage of Double-Strand Break Repair to the Cellular DNA Damage Response: Cell 93:477-486 (1998)	
YB	A13	TSUKAMOTO et al., Effects of Mutations of RAD50, RAD51, RAD52, and Related Genes on Illegitimate Recombination in Saccharomyces cerevisiae, Genetics 142:383-391 (1996)	
YB	A14	PAULL et al., The 3' to 5' Exonuclease Activity of Mre11 Facilitates Repair of DNA Double-Strand Breaks, Molecular Cell 1:969-979 (1998)	
YB	A15	TRUJILLO et al., Nuclease Activities in a Complex of Human Recombination and DNA Repair Factors Rad50, Mre11, and p95, J. Biol. Chem. 273(34):21447-21450 (1998)	
YB	A16	AJIMURA et al., Identification of New Genes Required for Meiotic Recombination in Saccharomyces cerevisiae, Genetics 133:51-66 (1993)	
YB	A17	JOHZUKA et al., Interaction of Mre11 and Rad50: Two Proteins Required for DNA Repair and Meiosis-Specific Double-Strand Break Formation in Saccharomyces cerevisiae, Genetics 139:1521-1532 (1995)	
YB	A18	PETRINI et al., Isolation and Characterization of the Human MRE11 Homologue, Genomics 29:80-86 (1995)	

Examiner Signature	<i>[Signature]</i>	Date Considered	11/30/04
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	
		Filing Date	August 26, 2003
		First Named Inventor	Pramod B. Mahajan
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	1264D
Sheet	3	of	5

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
YB	A19	FURUSE et al., Distinct roles of two separable in vitro activities of yeast Mre11 in mitotic and meiotic recombination, EMBO Journal 17(21):6412-6425 (1998)	
YB	A20	XIAO et al., Conditional gene targeted deletion by Cre recombinase demonstrates the requirement for the double-strand break repair Mre11 protein in murine embryonic stem cells, Nucleic Acids Res. 25(15):2985-2991 (1997)	
YB	A21	YAMAGUCHI-IWAI et al., Mre11 is essential for the maintenance of chromosomal DNA in vertebrate cells, EMBO Journal 18(23):6619-6629 (1999)	
YB	A22	WILSON et al., The role of Schizosaccharomyces pombe Rad32, the Mre11 homologue, and other DNA damage response proteins in non-homologous end joining and telomere length maintenance, Nucleic Acids Res. 27(13):2655-2661 (1999)	
YB	A23	DOLGANOV et al., Human Rad50 is Physically Associated with Human Mre11: Identification of a Conserved Multiprotein Complex Implicated in Recombinational DNA Repair, Mol. Cell. Biol. 16(9):4832-4841 (1996)	
YB	A24	LEWIS et al., Repair of Endonuclease-Induced Double-Strand Breaks in Saccharomyces cerevisiae: Essential Role for Genes Associated with Nonhomologous End-Joining, Genetics 152:1513-1539 (1999)	
YB	A25	MOORE et al., Cell Cycle and Genetic Requirements of Two Pathways of Nonhomologous End-Joining Repair of Double-Strand Breaks in Saccharomyces cerevisiae, Mol. Cell Biol. 16(5):2164-2173 (1996)	
YB	A26	NAIRZ et al., mre11S-yeast mutation that blocks double-strand-break processing and permits nonhomologous synapsis in meiosis, Genes & Development 11:2272-2290 (1997)	
YB	A27	TSUBOUCHI et al., A Novel mre11 Mutation Impairs Processing of Double-Strand Breaks of DNA during Both Mitosis and Meiosis, Mol. Cell. Biol. 18(1):260-268 (1998)	
YB	A28	HARTUNG et al., Accession No. Q9XGM2, Arabidopsis thaliana (Mouse-ear cress), (1999)	
YB	A29	HARTUNG et al., Accession No. AJ243822, Arabidopsis thaliana mRNA for Mre11 protein (MRE11 gene), (1999)	

Examiner Signature		Date Considered	11/30/04
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	
		Filing Date	August 26, 2003
		First Named Inventor	Pramod B. Mahajan
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	1264D
Sheet	4	of	5

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Y	A30	GERECKE et al., Accession No. AF178433, Coprinus cinereus DNA repair and meiosis protein Mre11 (mre11) gene, complete cds (1999)	
Y	A31	BIBIKOVA et al., Accession No. AF134569, Xenopus laevis putative nuclease Mre11 (MRE11) mRNA, complete cds (1999)	
Y	A32	BRODSKY et al., Accession No. AF132144, Drosophila melanogaster clone LD8638 endo/exonuclease Mre11 (mre11) mRNA, complete cds (1999)	
Y	A33	HARTUNG et al., Isolation of the Complete cDNA of the Mre11 Homologue of Arabidopsis (Accession No. AJ243822) Indicated Conservation of DNA Recombination Mechanisms Between Plants and Other Eucaryotes, Plant Gene Register PGR99-132 Plant Physiol. 121:132 (1999)	
Y	A34	NAKAMURA, Y., EMBL Accession No. AB010695, Arabidopsis thaliana genomic DNA, chromosome 5, P1 clone MDK4 (1998)	
Y	A35	JAESUNG et al., Accession No. PREV199800510932, Agrobacterium tumefaciens transformation of the thaliana mutants uvh1 and rad5 (1998)	
Y	A36	NAM et al., Agrobacterium tumefaciens Transformation of the Radiation Hypersensitive Arabidopsis thaliana Mutants uvh1 and rad5, MPMI 11(11):1136-1141 (1998)	
Y	A37	MYSORE et al., An arabidopsis histone H2A mutant is deficient in Agrobacterim T-DNA integration, PNAS 97(2):948-953 (2000)	
Y	A38	LEWIN, B., Most eukaryotic mRNAs are polyadenylated at the 3' end, Genes V 10:264-165 (1994), Oxford University Press, New York	
Y	A39	DOERKS, T., Protein annotation: detective work for function prediction, TIG 14(6):248-250 (1998)	
Y	A40	SMITH et al., The challenges of genome sequence annotation or "The devil is in the details", Nature Biotechnology 15:1222-1223 (1997)	

Examiner Signature		Date Considered	11/30/04
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	
		Filing Date	August 26, 2003
		First Named Inventor	Pramod B. Mahajan
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	1264D
Sheet	5	of	5

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Yp	A41	BRENNER, S.E., Errors in genome annotation, TIG 15(4):132-133 (1999)	
Yp	A42	BORK et al., Go hunting in sequence databases but watch out for the traps, TIG 12(10):425-427 (1996)	
Yp	A43	VAN DE LOO et al., An oleate 12-hydroxylase from Ricinus communis L. is a fatty acyl desaturase homolog, Proc. Natl. Acad. Sci. USA 92:6743-6747 (1995)	

Examiner Signature		Date Considered	11/30/04
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.